论文部分内容阅读
据Boice M 2016年10月6日[Cell,2016,167(2):405-418.]报道,利用嵌合抗原受体T细胞(CAR-T)作为靶向载体,用于治疗B细胞淋巴瘤。CAR-T作为免疫疗法和基因工程的使用取得新进展,CAR-T免疫疗法旨在给予免疫细胞所需要的信息来更好地将肿瘤细胞识别为外来的并攻击它们,从而增强免疫系统。美国纪念斯隆凯特琳癌症中心和法国雷恩第一大学研究人员通过研究发现,CAR-T未开发的起着靶向转运载体作用,即能够
According to reports by Boice M on October 6, 2016 [Cell, 2016, 167 (2): 405-418.], The use of chimeric antigen receptor T cells (CAR-T) as targeting vectors for the treatment of B cell lymphomas tumor. New advances have been made in the use of CAR-T as immunotherapy and genetic engineering. CAR-T immunotherapy aims to give immune cells the information they need to better recognize tumor cells as foreign and attack them, thereby enhancing the immune system. Researchers at the Memorial Sloan Kettering Cancer Center in the United States and at Rennes First University in France found that CAR-T, an undeveloped targeting transporter,